well fargo biotechnolog team host seri manag
meet healthcar investor confer san francisco
week overal met compani includ larg cap
small-mid cap compani coverag aggreg
meet reinforc posit outlook us biotechnolog
sector high convict idea therapeut categori
stood posit includ gene therapi gene silenc
target oncolog immunolog rare diseas
within coverag univers name stood posit
includ agtc qure within area gene
therapi area gene silenc cll
autl area cell therapi zyme area
target oncolog asnd area rare diseas
area neurolog
area immunolog area liver diseas
multi-therapeut platform compani enhanz royalti model
detail meet feedback follow report key
fabry/gaucher/cystinosi gene therapi updat worldsympodium
februari strength opportun across scd tdt bcma
car-t intern consist agtc vision gain xlrp gene
therapi posit later near term achm data
vector increas confid monotherapi activ ipsc-
deriv nk cell therapi improv respons durat til
broaden opportun beyond melanoma cervic cancer
acceler cll allo-car-t program
differenti autl car-t adult dlbcl versu
approv standard prospect hemophilia gene therapi
durabl partner strength oxbryta launch execut
ahead expect launch metric updat result
confid explor maverick data broader
opportun hfpef near term enthusiasm btki data ms
differenti across multipl autoimmun diseas strengthen
rational rapt inhibitor potenti oral
dupix atop dermat ad evolut busi model
retain commerci right innov aso therapeut across
multipl late stage opportun potenti earlier larger
opportun asnd transcon pth strong path forward data
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani cover
research report result investor awar firm may
conflict interest could affect object report
investor consid report singl factor make
conduct interim analysi galactic-hf omecamtiv mecarbil
trial congest heart failur
updat result myeloma bcma half-lif extend bite
azn expect top-lin phase data thymic stromal lymphopoietin antagonist
tezepelumab asthma
kra phase solid tumor updat data phase nsclc clinical/regulatori updat
expect strong guidanc set januari incorpor otezla contribut
signific risk head-to-head studi result otezla vs oral inhibitor given
remain rel weak efficaci profil otezla
compani report secur llc estim price
aducanumab bla fda accept
expect overhang around februari patent decis tecfidera see greater
downsid risk upsid potenti
believ approv aducanumab unlik neither support statist analysi
phase result polit consider approv would potenti set cours
futur alzheim develop wrong direct would subject patient toxic without
clear benefit establish bad preced allow bla file fail alzheim drug
compani report secur llc estim price
filgotinib approv rheumatoid arthriti eu/jp approv
fda review car-t bla mantl cell lymphoma
filgotinib phase data ulcer coliti snda
yescarta data adult acut lymphoblast leukemia sbla
glpg expect phase rocella data osteoporosi
expect strong earn guidanc januari base continu growth hiv sale stabil
hcv declin margin expans ration spend
expect increas busi develop potenti focu immunolog cancer
antibodi therapeut blood disord rare diseas
compani report secur llc estim price
dupix phase liberty-voyag asthma data old
eylea-high dose cadela data wet age-rel macular degener
expect continu strong growth dupix sale increas contribut earn
expect signific eylea market share loss anti-vegf competitor beovu brolucizumab
loss volum frequent eylea inject go trial beovu
net impact expect slow earn growth multipl contract
compani report secur llc estim price
xlrp phase data updat central dose patient januari
achromatopsia phase data updat light toler
new data visual acuiti color discrimin januari
end-of phase meet fda xlrp pivot studi potenti pivot studi
initi
expect data xlrp patient dose central confirm data suggest
improv visual acuiti letter improv visual field sensit
expect data achromatopsia confirm data
clinic signific improv light toler support addit benefit
color discrimin visual acuiti
expect agreement fda pivot develop xlrp support visual acuiti visual field
sensit approv endpoint
well fargo biotechnolog team met agtc manag investor meet
san francisco focu meet ceo sue washer cso dr mark shearman cfo
sullivan compani aav gene therapi product candid treatment xlrp
achm
focu xlrp program agtc highlight recent phase demonstr
clear separ visual sensit respond non-respond earli
month improv visual acuiti timelin consist expect timelin aav gene
express agtc also note respons rate rang respons rate
base luxturna approv competitor respons rate
term regulatori path agtc expect clariti upon end-of-phas meet although
bilater treatment visual sensit endpoint expect
focu program agtc analyz data
expect compani day data includ patient
studi although recal first patient surgic variabl thu inform data
expect patient patient studi efficaci endpoint
chang light sensit measur self-report toler light log lux scale agtc
suggest lux chang clinic meaning believ endpoint could
use regulatori endpoint
compani report secur llc estim price
updat gene therapi fabri diseas
initi data gene therapi gaucher diseas
initi data gene therapi cystinosi
expect data updat phase phase studi gene therapi fabri
diseas confirm vcn stabil longer term follow sustain aga enzym activ
sustain level high level inclus reduct kidney biopsi
expect plato optim vector system improv condit regimen support improv
drug product vcn engraft gene modifi cell peripher vcn aga activ
reduct fabri diseas
possibl breakthrough therapi design btd and/or rmat design
expect regulatori updat support acceler approv path expans
expect earli result gaucher diseas cystinosi benefit
plato product process improv demonstr earli evid gene product
biotechnolog team met manag investor
meet san francisco focu meet ceo geoff mackay cso dr chri mason
cfo erik ostrowski compani expand pipelin lentivir gene therapi
lysosom storag diseas lsd upcom data program fabri diseas gaucher
diseas cystinosi broader outlook
focu lead gene therapi fabri diseas highlight patient
enrol across phase phase recent data suggest
durabl benefit extend month first phase patient initi month data
phase support reduct regulatori endpoint inclus data updat
expect worldsymposium februari expect month data phase
patient month data patient month data patient initi data transduct
effici drug product vcn first patient treat optim plato platform
well longer term durabl data beyond month phase continu target
discuss fda rmat design registr strategi could includ expans
phase
addit focu broader pipelin highlight first patient consent avr-rd-
treatment gaucher diseas expect dose use plato platform
also highlight first patient treat octob ucsd ind month data
expect worldsymposium focu dpvcn peripher vcn potenti earli effect
cystin reduct given high diseas burden limit treatment option believ
current phase adapt registr studi look transfer ind
compani report secur llc estim price
ide-cel bla file approv relapsed/refractori myeloma
lentiglobin gene therapi data updat sickl cell diseas scd studi
initi pivot studi
zynteglo lentiglobin gene therapi launch europ beta-thalassemia
expect earli bla file bcma car-t ide-cel support approv
opportun relapsed/refractori myeloma
myeloma patient death us/eu year see salvag
opportun bcma-direct therapi larger opportun earlier use
line set studi on-going soon initi line therapi ide-cel
expect opportun patient receiv multipl line
therapi sequenti bcma-direct
expect increas focu lentiglobin gene therapi sickl cell diseas scd prospect
earlier approv path result base high cure rate patient heavi diseas
burden high rate vaso-occlus crise voc
launch expect zynteglo gene therapi beta thalassemia rel low
expect invest time secur reimburs pre-identif elig
patient could provid upsid surpris
well fargo biotechnolog team attend manag updat meet bluebird bio
investor confer san francisco focu meet ceo nick
leschli senior manag team member upcom bla bcma car-t
therapeut myeloma progress launch zynteglo lentiglobin gene therapi
beta thalassemia tdt europ potenti regulatori path lentiglobin gene therapi
sickl cell diseas scd
focu bcma car-t therapeut myeloma upcom bla highlight
top-lin pivot phase karmma data suggest orr cr rate month
durat respons dor establish high bar competitor question
cross trial comparison competitor jnj bcma car-t therapeut highlight
advanc patient recent proxim last treatment failur
day versu month also highlight aggress strategi partner move
earlier treatment on-going trial line myeloma
consider key variabl like tumor burden tumor biolog role mainten therapi
next-gener bcma car-t therapeut suggest earlier evid
target cell featur memori cell phenotyp potenti grate persist although
suggest earli assess longer term clinic implic
addit focu lentiglobin gene therapi highlight launch germani
first qualifi treatment center agreement value-bas reimburs model
highlight effort gain accept valu base model bia toward singl up-
front payment suggest provid expertis templat eu countri
ultim us payer potenti extend sickl cell diseas scd well lentiglobin
gene therapi scd highlight reduct voc support transform
clinic outcom patient come high voc burden detail
registr path werent provid suggest discuss on-going fda rang
approv path file current result wait longer phase
compani report secur llc estim price
initi phase develop huntington diseas gene therapi
phase studi data hemophilia
advanc next aav gene therapi candid
see upsid potenti phase studi result expect best-in-class profil
factor ix activ confirm hemophilia meaning huntington efficaci data may
emerg believ qure could see later upsid potenti advanc efficaci
updat competitor ionis/roch gene silenc earlier
well fargo biotechnolog team met uniqur qure manag investor
meet san francisco focu meet ceo matt kapusta evp research
product develop dr sander van devent evp oper dr kuta svp ir maria
kantor compani gene therapi pipelin includ hemophilia
huntington diseas overal program appear track phase hope-b
data expect initi safeti data intraparenchym gene therapi
huntington expect new ind year hemophilia
focu gene therapi hemophilia qure highlight patient
treat complet dose expect late top-line data
phase data highlight provid high level confid hope-b result mean
factor ix activ cur rang earlier patient dose
support durabl year qure expect file bla suggest roughli
month follow data prepar file patient us
europ qure suggest signific initi opportun patient receiv prophylact treatment
well demand dose increas frequenc bleed busi model
reimburs still assess qure believ one-tim payment like
us highlight annual cost factor ix replac lifetim cost
support rang potenti price although acknowledg go
beyond might tough
addit focu gene therapi huntington diseas qure highlight
initi phase placebo control studi intraparenchym dose patient
dose cohort patient dose cohort broader enrol gate first
patient cohort activ imit surgeri fda request advanc
stage patient smaller putamen caudat volum due atrophi make patient
select challeng overal dose target full coverag striatal structur
putamen caudat bilater inject
hemispher preclin data highlight local anterograd retrograd transduct
neuron htt knockdown striatum cortex evid motor
cognitive/neuropsych benefit initi focu safeti qure note csf reduct
htt would reflect true effect suggest potenti earlier effect motor symptom
cognit benefit neurofila light chain nfl expect increas initi
intra-striat inject qure expect actual declin time reduc brain atrophi
compani report secur llc estim price
final phase data cohort vy-aadc gene therapi parkinson diseas
medic meet
phase data vy-aadc gene therapi parkinson diseas partner neurocrin
ind file gene therapi huntington diseas follow
preclin data first patient dose
believ establish predict therapeut profil vy-
aadc gene therapi parkinson proof-of-concept achiev gene express aadc enzym
putamen increas convers levodopa dopamin dramat reduct levodopa dose
improv approv endpoint on-tim without troublesom dyskinesia posit phase
result could repres signific valu driver could benefit improv protocol
manag dyskinesia optim dose deliveri leverag simpl dopamin biolog
effect phase gene therapi program huntington
meaning efficaci data believ could benefit huntingtin silenc
program competitor like qure final sever gene therapi program
preclin develop includ al friedrich ataxia potenti in-licens
gene therapi asset see addit option valu beyond
biotechnolog team met manag investor meet
san francisco focu meet ceo andr turenn dr omar khwaja cfo
allison dorval compani neurolog gene therapi pipelin includ vy-aadc
parkinson diseas huntington diseas
focu neurocrin bioscience-partn vy-aadc parkinson diseas plan
report data phase studi medic confer term
expect data expect show signific differ motor function
patient treat cohort studi vs natur histori
popul patient advanc diseas baselin modifi hoehn yahr scale
stage baselin also note previous report data show
improv modifi hoehn yahr scale score expect
natur histori set also plan report data studi evalu
posterior administr vy-aadc also continu dialogu fda regard
design pivot trial continu believ size
trial patient plan continu enrol patient
get amend approv irb ensur smooth incorpor protocol chang
expect initi studi year readout restore-
studi importantli note improv protocol manag dyskinesia dose
reduc levodopa result less dramat dose adjust believ bode
well studi result
addit focu wholly-own huntington diseas plan
submit ind applic studi initi recal deliv
gene therapi putamen thalamu regard compet approach administr
putamen caudat note caudat degener earli diseas cours
make tough neurosurgeri target also appropri anim model caudat
degener anim model thalamu administr safe mediat broad
distribut cortex also highlight sinc last present preclin data
htt mrna lower adult nhp week follow treatment htt level
continu declin meaning
addit updat includ nomin develop candid friedreich ataxia
program
compani report secur llc estim price
tegsedi launch progress us/eu addit eu countri launch latin america launch
partner therapeut
waylivra launch europ potenti regulatori decis fda
phase data earli next-gener lica aso includ
nafld/nash akcea-apociii-lrx elev triglycerid
potenti new asset acquisit either parent compani
expect tegsedi sale hattr polyneuropathi acceler gain market share
competitor onpattro suggest prior survey work expand territori launch europ
latin america expect waylivra sale potenti appear modest could see upsid
surpris could gain fda approv up-front payment
develop nafld/nash liver diseas believ phase
data earli could surpris upsid particularli given investor focu nafld/nash
final global high-touch rare diseas endocrin hematolog diseas commerci
infrastructur built see signific upsid potenti in-licens parti asset includ
potenti gene therapi expect sever deal
compani report secur llc estim price
addit patient data vertex-partn gene-edit cell therapi
sever hemoglobinopathi sickl cell diseas scd transfusion-depend beta
thalassemia tdt longer term result first scd first tdt patient treat
initi data phase studi gene-edit allogen car-
initi phase studi gene-edit allogen bcma car-t therapeut
potenti updat regen medicin program includ gene edit
pluripot stem cell deriv pancreat islet cell type diabet
gene therapi gene edit sickl cell diseas scd transfusion-depend beta
thalassemia becom crowd area believ opportun signific accommod
multipl player estim roughli patient candid scd gene therapi alon
us repres opportun mani year earli result suggest
consist pan-cellular express anti-sickl fetal hemoglobin hbf earli clinic benefit
term transfus independ tdt elimin vaso-occlus crise voc scd
expect longer term follow patient experi confirm consist result area off-
the-shelf allogen car-t therapi even crowd howev believ scope crsp
develop beyond competitor breadth emerg pipelin target bcma
well ksq-partner asset also beyond competitor believ valuat
allogen car-t leader allogen provid guid potenti allogen car-t valu
crsp yet reflect current share price view partner program vertex well
regen medicin program could drive increment valu view
biotechnolog team met crispr crsp manag
investor meet san francisco focu meet ceo dr samarth kulkarni
head research develop dr toni ho progress compani
therapeut pipelin key mileston
focu ex vivo gene edit product candid crsp highlight recent
clinic data first patient beta-thalassemia studi sickl cell diseas
scd studi significantli de-risk hemoglobinopathi program risk-reward
profil reset focu rotat execut term catalyst beta-
thalassemia scd phase studi crsp expect report addit data studi
year longer follow-up initi two patient well data addit patient
treat studi
focu wholly-own allogen car-t program immuno-oncolog crsp
highlight despit high competit densiti field compani may maneuv
ahead competit virtu nimbl execut rel larger competitor mid-
crsp expect report earli data on-going phase studi allogen anti-
car-t product candid malign
crsp note potenti benefit gene-edit insulin-produc cell vs first-gener non-
gene edit cell includ elimin need life-long immuno-suppress well
potenti prevent cell exhaust crsp also highlight addit earli pipelin program
includ vivo gene edit program glycogen storag diseas ia gsd ia duchenn
muscular dystrophi dmd myoton dystrophi type
compani report secur llc estim price
spinraza sale spinal muscular atrophi sma emerg competit gene therapi
zolgensma oral splice modifi risdiplam
tegsedi sale hattr polyneuropathi rel perform rna therapeut competitor
phase open-label extens ole data antisens oligonucleotid aso therapeut
huntington diseas
potenti regulatori updat partner roch potenti acceler approv file
huntington
pipelin updat across program includ high profil program al new program
like lefora alexand prion diseas new program cystic fibrosi oral aso
nafld/nash
expect spinraza continu beat consensu estim grow competitor entrant
new therapi ad backbon spinraza instead place spinraza expand
still under-penetr adult sm newer entrant less data beyond current
territori expert feedback suggest patient unlik withdrawn effect sma
therapi particularli full function hasnt restor combin therapi like
pursu support continu growth spinraza term pipelin believ roch
maintain guidanc potenti acceler approv huntington albeit push
suggest like benefit observ ole studi believ updat
meet april possibl see signific option valu broader pipelin updat particularli
given advanc potenc lica lrx conjug progress oral inhal aso drug
candid posit partner comment program al nafld/nash clot factor xi hepat
cv diseas new ceo comment retain commerci right particularli emerg
compani report secur llc estim price
re-initi phase multipl ascend dose mad studi anti-mir therapeut
autosom domin polycyst kidney diseas adpkd
potenti lift second part partial clinic hold allow longer durat dose
initi phase short-term dose studi adpkd assess safeti pk
biomark pd activ
overal believ target microrna mir anti-mir therapeut proven difficult
expect downstream effect microrna appear complex fulli understood
view focu target believ risk longer term dose hard
assess point correl preclin data human efficaci data adpkd
preclin mous model demonstr decreas cyst format improv kidney weight
improv kidney function believ potenti differ rel contribut mir-
human diseas adpkd difficult quantifi given balanc sheet concern extend
timelin gener biomark data less clear correl biomark regulatori
endpoint adpkd would take wait-and-se approach rgl share
compani report secur llc estim price
phase updat hemophilia gene therapi month follow first high
progress updat partner phase lead-in phase enrol potenti initi patient
dose phase treatment phase
initi phase data latest gene therapi program gene therapi fabri diseas
potenti updat partner sanofi ex-vivo gene edit beta thalassemia
potenti updat ex-vivo allogen car-t program cancer partner gilead
proprietari car-treg program prevent kidney transplant reject potenti auto
believ under-valued rel less advanc gene therapi gene edit cell
therapi peer signific upsid potenti gene therapi hemophilia alon view
advanc partner phase signific valid program expect phase
data confirm durabl factor viii activ beyond month support better durabl
effect base faster rise factor viii activ higher steadi state factor viii longer term
durabl factor viii activ lower dose cohort seen competitor believ valid
hemophilia gene therapi increas confid gene therapi program use
aav expect posit data fabri diseas gene therapi beyond vivo gene
therapi hemophilia fabri diseas see signific upsid potenti updat ex-
vivo gene edit beta thalassemia tdt potenti initi data sickl cell diseas
scd believ earli comparison gene edit competitor potenti misplac given
signific differ patient attribut includ age final see signific option valu
allogen car-t progress well car-treg updat along advanc next-gener
effort vivo gene edit
well fargo biotechnolog team met sangamo therapeut manag
investor meet san francisco focu meet ceo dr sandi macra
cfo sung svp corpor commun ir mcdavid stilwel compani
broad genom platform rang gene therapi ex vivo gene edit vivo gene
edit primari focu hemophilia focu fabri
diseas betathalassemia ex vivo gene edit cartreg cart
highlight meet includ hemophilia data demonstr rapid
onset factor viii express less variabl bode well durabl
effect versu competitor longer follow beyond month data
partner pfizer continu advanc phase manag provid detail
around econom note mid-teen low royalti net sale left potenti
precommerci mileston progress gene therapi fabri diseas
enrol across dose cohort expect edit effici roughli
manag believ adequ provid benefit betathalassemia scd
key differ competitor includ patient age cell dose make cross trial
comparison difficult cartreg trial expect initi data
focu data kidney biopsi demonstr traffick cartreg relev site
preliminari effect immun microenviron
compani report secur llc estim price
futil analysi registr trial advanc synovi
myxoid round cell liposarcoma sarcoma
updat tcr phase durabl respons data sarcoma
complet dose escal data tcr hepatocellular carcinoma
interim safeti respons data phase surpass trial next-gen tcr adp-
initi tcr combin trial
continu believ valid tcr therapeut beyond narrow area synovi sarcoma
difficult achiev given lack respons solid tumor singl antigen-target approach
includ believ polyclon approach achiev
til therapeut necessari adequ address multi-antigen tumor rapidli
mutat remain skeptic durabl respons maintain singl antigen tcr
approach addit potenti mismatch exogen tcr endogen tcr chain
associ off-target effect would take wait-and-se approach adap well
tcr therapeut effort would prefer til approach iovanc
adaptimmun adap announc initi respons solid tumor deliv spear t-cell
platform includ confirm partial respons pr one liver cancer patient phase
trial posit subject adequ afp protein blood tumor
littl afp protein noncancer liver tissu confirm pr one melanoma patient phase
trial subject posit tumor unconfirm pr one
metastat gastroesophag junction cancer patient surpass trial subject
posit tumor unconfirm pr one head neck cancer patient phase
trial expans phase subject posit tumor phase
trial patient synovi sarcoma myxoid round cell liposarcoma mrcl
compani also note advers event compar patient experienc
receiv cytotox chemotherapi cancer immunotherapi rate consist
t-cell therapi
compani report secur llc estim price
open site registration-target trial adult
phase alexand data car-t adult dlbcl follow phase
interim phase dose escal data car-t cell lymphoma
pre-clin data car-t new binder
phase initi bcma car-x myeloma
ind car-t subsequ clinic develop pediatr solid tumor
believ autolu autl success navig sever challeng issu
sharehold issu manufactur issu resolv attract valuat rel lead cell
therapi peer within area next-gener car-t therapeut believ autl
distinguish crowd differenti efficaci approv car-t therapeut kymriah
yescarta approv path least one next-gener car-t therapeut
adult believ adult opportun greater pediatr
opportun superior safeti could ultim give domin posit broader
car-t space includ pediatr dlbcl current sale run rate
believ success bode well rest autl pipelin includ t-
cell lymphoma dlbcl earlier program like next-gener bcma car-t myeloma
solid tumor repres signific option valu view
well fargo biotechnolog team met autolu autl manag investor
meet san francisco focu meet ceo dr christian itin car-t
next gen car-t target dual
myeloma target car-t employ one ault modular cassett
improv cell function autl also introduc new program modul first step
highlight meet includ initi adult acut lymphoblast leukemia
registration-en studi goal file bla trial autl
expect show doubl respons rate event-fre surviv ef compar
blincyto note phase minimal-residu diseas neg cr
ef patient receiv closed-process manufactur product
autl expect data approxim diffus larg cell lymphoma patient
treat car-t autl believ demonstr
superior toler profil current approv car-t product compani need
see sustain cr rate also superior current approv product
order initi registr enabl trial
autl expect present initi phase data posit cell
lymphoma initi clinic develop myeloma employ dual
target myeloma antigen includ bcma well potenti incorpor one
autl modular program cassett aim improv car-t efficaci persist
autl expect initi clinic develop compani first allogen car-
product use program cassett encod tcr sequest protein
result tcr degrad pre-clin model abl prevent develop
compani report secur llc estim price
complet sale cell therapi manufactur facil strateg partner
resolut clinic hold dual-switch car-t
execut strateg partnership futur develop rivo-cel
phase multi-dos data psca go-car-t pancreat gastric prostat cancer
believ bellicum pharmaceut blcm imc activ switch caspacid safeti switch
technolog cell therapi could broadli leverag across car-t car-nk therapeut
cancer recent licens caspacid safeti switch technolog md anderson high profil
car-nk therapeut valid technolog potenti attract addit partnership
interest primari focu compani proprietari gocar-t go-car-nk program would
note initi data psca-direct gocar-t therapeut heavili pre-treat pancreat cancer
suggest improv expans car-t persist patient stabl diseas
tumor shrinkag follow singl rimiducid dose potenti enhanc efficaci repeat
rimiducid dose importantli view gocar-t therapeut
signific potenti valu driver see potenti lift clinic hold ind approv
key catalyst stock
biotechnolog team met bellicum blcm manag investor
meet san francisco focu meet ceo fair cfo atabak mokari
compani switchabl gocar-t newli announc gocar-nk program
blcm lead go-t use small molecul rimiducid activ psca
blcm conduct phase dose escal expans trial current blcm
enrol patient cohort evalu weekli rimiducid blcm expect
commun top-lin data cohort focu safeti everi day
rimiducid dosing/rep car-t activ whether repeat rimiducid deepen level
clinic activ report cohort evalu singl dose rimiducid
blcm present translat data includ pre post treatment biopsi cohort
asco-gi later januari
dual switch go-t includ go-switch activ
caspase-activ suicid switch use set off-target toxic ind
file put clinic hold fda blcm conduct teleconfer fda late
clarifi fda request addit data result blcm conduct addit in-vitro
studi defin risk off-tumor on-target toxic confirm car-t
activ requir rimiducid high antigen load blcm expect complet studi
respond fda provid timelin updat absenc ind
develop program bcma-target gocar-nk would compani
first shelf cell therapi goal file ind next month follow
select proprietari bind domain optim vector complet pre-
ind studi gocar-nk also contain signal domain support expans
persist nk cell in-vivo gocar-nk product would util proprietari mc
domain car-t product blcm note mc increas nk cell persist
innat kill potenc bcma space crowd blcm note use valid
target remov key variabl follow detail competitor analysi blcm believ
propos develop timelin off-th shelf nk cell product target bcma
competit shelf strategi
part refocus compani away commerci rivo-cel blcm note
compani remain discuss small number parti potenti interest
acquir rivo-cel manag expect secur strateg partner compani
manufactur facil action would provid non-dilut capit reduc overhead low
teen million annual ensur uninterrupt cell therapi manufactur blcm product
extend cash runway view
compani report secur llc estim price
interim phase data allogene-partn allogen car-t cell
phase data aml follow potenti initi phase registration-en
cohort aml patient
expans on-going phase trial relapsed/refractori
initi phase dose escal data multipl myeloma
complet smart commercial-support manufactur facil
view cellecti cll attract valu rel cash hand ownership crop scienc
compani royalti arrang cancer target allogen car-t leader
allogen inde cash ownership royalti
allogen car-t program market cap allogen believ cll under-valu
rel partner program valu assign multipl proprietari unpartn program
focu proprietari allogen car-t program view updat
aml signific potenti valu driver signific valid target
disproport upsid potenti opinion
well fargo biotechnolog team met cellecti cll manag investor
meet san francisco focu meet ceo dr andr choulika dr francisco
estev vice-president clinic develop simon harnest vice-president corpor strategi financ
compani allogen car-t portfolio includ wholli own acut myeloid
leukemia cell malign myeloma
cll enrol multipl myeloma subject dose level
cells/kg complet dose-limit toxic dlt period first patient
heavili pre-treat prior regimen includ daratumumab cll open
subsequ trial day dlt period patient
follow opportun enrol patient simultan patient fail bcma-
target agent elig trial cll note high level interest trial
patient wait line enrol
cll also dose first adult acut lymphoblast lymphoma patient
trial trial evalu dose dose level
day dlt period patient day patient cll
decid use diffus larg cell lymphoma dlbcl studi whether
new ucart develop diffus larg cell lymphoma dlbcl
cll expect provid updat shortli note current product differ
product use time cll dose acut myeloid leukemia patient
current studi dose level plan evalu
cll ad alemtuzumab precondit studi rather use standard
cll expect partner allogen present data cell lymphoma
includ dlbcl bcma cll expect
 manufactur site come on-lin allow compani suppli initi two later
product includ next gener smartcar product integr compani
experi synthet biolog repurpos gene includ tcr
optim express cell function
compani report secur llc estim price
phase optimab data think deplethink trial car-t aml mid-
interim phase data car-t expect allow comparison
complet manufactur batch allogen car-t
enrol addit subject refractori metastat
cyad expect commun go-forward strategi aml
file ind gener non-vir allogen bcma car-t
file ind gener non-vir allogen car-t
believ celyad cyad valu could justifi alon intellectu properti ip cover t-
cell receptor tcr knockdown employ broadli effort creat allogen car-t therapeut
competitor addit believ differenti approach shrna creat non-gene-edit
allogen car-t could highli leverag proprietari develop next-gener
allogen car-t therapeut well partnership other car-t field
would look progress leverag proprietari develop off-the-shelf allogen
car-t therapeut includ target target bcma support
current valuat believ upsid potenti particularli depend demonstr
consist clinic efficaci lead program target includ cyad-
follow inconsist data first-gener aml believ next-
gener effort earli data autolog manufactur new optimab platform
well autolog use shrna knockdown ligand mica micb new effort
allogen critic recoveri cyad share given rel short cash runway
would suggest limit time establish clear efficaci next-gener car-t
well fargo biotechnolog team met celyad cyad manag investor
meet san francisco focu meet ceo filippo petti cso david gilham
first-in-class autolog car-t non-genet engin allogen
car-t bcma
think trial acut myeloid leukemia aml cyad observ clinic
activ repeat dose monotherapi subsequ explor varieti strategi
cyclophosphamide/fludarabin lymphodeplet without clear benefit part due recruit
patient signific diseas burden greater age cyad current enrol
patient manufactur use optimab process increas car-t potenc
focu patient favorable/intermedi european leukemia net diseas wild type
allow bridg chemotherapi data expect
includ shrna target ligand mica/b target reduc fratricid
data cyad intend complet evalu autolog car-t aml
need show minimum complet respons rate durabl least month
move program forward
colorect cancer cyad manufactur batch non-gen engin
tim-bas allogen car-t target use optimab goal enrol addit
patient alloshrink advanc diseas trial cyad note initi data
compani seen respons irrespect ra mutat statu patient
report on-going stabl diseas meet remain sd without addit
treatment cyad believ addit optim could includ dose car-t
dose folfox vs current dose use altern chemotherapi
cyad expect file ind next-gener bcma-target allo-
car-t leverag shrna target tcr cyad believ non-gen engin
strategi develop allogen car-t offer rapid differenti strategi vs gene
engin strategi leverag ad addit function optim cell
function across portfolio
compani report secur llc estim price
initi data ipsc-deriv nk therapeut expect
phase data protmun hematolog malign
ind ipsc nk ipsc -t expect ind ipsc bcma
updat phase data expect ipsc nk cell product plu monoclon antibodi
continu believ disrupt technolog cell
therapi space best opportun achiev true off-the-shelf car-t car-nk therapeut
true drug-lik properti in-lin broadli use antibodi therapeut demonstr abil engin
singl cell level produc ready-to-us uniform product high scale low cost good
uniqu could transform cell therapi space view follow initi data ipsc-
deriv nk-cell therapeut believ safeti abil repeat dose earli
evid antitumor efficaci establish posit well meaning
data flow believ fate first car-nk therapeut repres signific
valu driver base promis result compet car-nk therapeut md
expect demonstr complet respons cr earli dose escal
differ nk-cell sourc ipsc vs cord-blood deriv differ engin featur md
anderson car-nk therapeut believ earli evid tumor clear aml
suggest ipsc-deriv nk-cell behav like normal nk cell anti-tumor effect
start dose sever fold higher md anderson saw believ
significantli de-risk head success believ
ipsc-deriv nk cell approach could rapidli leverag target includ high-profil
therapeut recent announc fda clear second investig new
drug ind applic ipsc-deriv off-the-shelf natur killer nk cell product
advanc solid tumor combin egfr monoclon antibodi
mab combin recal current evalu monotherapi acut
myeloid leukemia aml combin mab advanc b-cell
lymphoma bcl expect initi phase trial evalu egfr
mab later
addit announc public preclin proof-of-concept data
express novel high-affin non-cleav variant journal blood
vivo shown demonstr superior mainten express increas
level cytokin product upon activ compar healthi donor-deriv peripher
blood nk cell vivo model human lymphoma mab demonstr
signific improv median surviv exceed day compar mab
alon combin healthi donor-deriv peripher blood nk cell
convey median surviv day addit mab show surviv
benefit xenograft model ovarian carcinoma
compani report secur llc estim price
complet enrol registration-en cohort lifileucel melanoma trial
complet enrol cohort cervic cancer trial ahead expect bla
phase data sarcoma ovarian cancer partner md expect
biolog licens applic bla submiss til therapeut lifileucel melanoma
data moffitt-sponsor trial til opdivo combin nsclc expect
follow promin acquisit car-t leader kite juno believ cell
therapi remain larg restrict hematolog malign like aml dlbcl solid
tumor success remain elus car-t engin tcr therapeut believ
signific scarciti valu consist solid tumor success seen iovanc til
therapeut across melanoma cervic cancer would suggest one cell
therapi name believ platform broad polyclon effect til
therapeut much like succeed multi-antigen rapidli mutat solid tumor
singl antigen approach car-t tcr therapeut product perspect believ
overal respons rate orr primari metastat melanoma patient
month median durat respons lead til therapeut lifileucel go support signific
commerci opportun bode well pivot studi success close patient
experienc object respons last month longer fail respond
therapi believ efficaci firmli establish support pivot studi success specif
could use melanoma patient follow therapi certainli patient
treatment option believ orr cr rate month median durat
respons advanc cervic cancer equal impress bode well second pivot studi
success signific increment commerci opportun recognit potenti valu
melanoma cervic cancer may reason reflect current valuat see upsid potenti
solid tumor indic potenti data includ non-smal cell lung cancer nsclc
head neck cancer scchn tripl neg breast cancer tnbc along earli result
peripher blood lymphocyt pbl therapeut cll final commerci scale manufactur
signific ip know-how commerci feasibl process broad solid tumor success
believ industri way establish high barrier entri
well fargo biotechnolog team met iovanc biotherapeut manag
investor meet san francisco focu meet cfo tim morri
compani pipelin gener tumor infiltr lymphocyt til product next-
lead til lifileucel checkpoint inhibitor-refractori melanoma compani expect
complet enrol registr cohort end follow-
report top-lin data includ data present perhap esmo
updat result phase non-registr cohort median month
follow-up median durat respons yet reach
cervic cancer amend protocol follow end phase meet
push back complet enrol top-lin data expect month later
data cervic within two month pre-bla meet melanoma file
lifileucel bla time
continu enrol advanc head neck cancer patient separ
trial compani expect make decis possibl cohort expans registr
later earlier line therapi continu enrol patient basket trial
nave melanoma non-smal cell lung cancer til keytruda relaps
refractori nsclc note timelin enrol first month initi
data present may occur later year addit cohort design enrol
subject compani will make develop decis earli strong signal
compani report secur llc estim price
phase data opdivo combin gbm expect
initi phase data car-t
potenti enrol updat nci use neoantigen tcr
share recov renew enthusiasm around cell therapi
controllable-gen therapi program believ actual technic risk signific around lead
program tcr therapeut target kra famili neo-antigen non-smal cell lung cancer nsclc
kras-mut solid tumor next-gener sleep beauti engin car-t
leukemia lymphoma control gene therapi glioblastoma multiform gbm
particular believ t-cell repertoir may narrow tcr cell therapi target kra neo-
antigen would highlight short durat respons kra target small molecul drug
suggest potenti rapid mutat away primari kra target overal believ sleep
beauti non-vir engin car-t tcr cell yet valid competit viral
approach mani year test cell viabil remain risk kra tcr car-
program final regard control gene therapi gbm believ singl arm
overal surviv os data difficult assess multipl potenti contributor bia result
result patient elig receiv surgic resect compar result
larger trial sicker patient surgic elig would note prior result fail
phase pseudoma exotoxin strong singl arm phase data appropri frame
refer overal opportun may signific opportun success believ
enthusiasm outpac execut would take cautiou view
compani report secur llc estim price
interim phase data nk cell engag lo tf
phase result trial r/r hodgkin lymphoma
initi data bispecif innat cell engag expect
given increas interest enthusiasm area nk-cell therapeut bispecif t-cell engag
emerg recent american societi hematolog annual meet decemb view
repres ultim converg two therapeut categori
leadership posit bispecif nk-cell engag promin collabor roche/genentech
believ nk-cell engag platform pipelin abil address limit
nk-cell therapeut term durabl effect t-cell engag term toxic expect
increas investor interest pipelin potenti increas collabor interest
well expect progress phase pivot studi bispecif nk- cell engag
peripher t-cell lymphoma well earli data bispecif nk-cell engag
solid tumor repres signific potenti valu driver follow strong valid
earlier studi follow nomin two addit nk-cell engag preclin develop
addit target licens genentech see signific option valu emerg pipelin
potenti upsid new target identif
well fargo biotechnolog team met amfd manag investor
meet san francisco focu meet ceo dr gregori gin head
investor relat compani bispecif base innat cell engag includ
target target egfr
lead program relapsed/refractori peripher cell lymphoma enrol across
global site redirect trial on-going expect provid progress updat
afmd partner md anderson receiv approv ind evalu cord blood-deriv
nk cell pre-load licens bcma bispecif innat cell engag
myeloma commun progress outsid afmd control
solid tumor enrol patient tumor known express egfr phase
dose escal trial site current expect expand enrol
site fda allow amfd initi dose level expect minim
effect dose requir one week interv patient phase expect
evalu dose level dose weekli open expans cohort
propos expans cohort line colorect cancer line non-smal cell lung
cancer line announc indic announc indic patient enrol
trial receiv baseline-biopsi later stage develop expect
specif address variabl kra mutat statu prior exposur
announc two new pre-clin asset move ind
enabl studi year asset leverag afmd platform effici gener
dozen candid bispecif nk cell engag allow optim epitop select
nk target cell geometri select tumor antigen target compani
screen potenti candid demonstr target valid ultim fail
monoclon antibodi subsequ bispecific/antibodi drug conjug cross evid
role innat immun tumor
compani report secur llc estim price
cantata phase result telaglenastat cabometyx rcc expect
telaglenastat ibranc phase dose escal data identifi kra mutat
nsclc expect
phase biomark data cystic fibrosi
chemo combin phase data mss stabl
calithera face pivot year random phase cantata data telaglenastat
cabozantinib advanc renal cell cancer rcc base prior posit entrata data
telaglenastat everolimu advanc rcc doubl progress free surviv
well strong preclin data combin telaglenastat cabozantinib believ
cantata strong basi success greater upsid potenti downsid risk
cantata data repres binari risk event believ done good job
diversifi risk initi multipl investig sponsor trial ist telaglenastat
variou combin includ inhibitor palbociclib kras-mut nsclc broad
phase develop arginas inhibitor partner monotherapi
combin keytruda checkpoint inhibitor cpi refractori naiv patient phase
develop novel arginas inhibitor patient cystic fibrosi believ move
cystic fibrosi novel potenti complementari approach arginas inhibit could
repres signific valu driver phase data matur
biotechnolog team met manag
investor meet san francisco focu meet ceo dr susan molineaux
dr keith orford svp financ secretari stephani wong vice-president ir strategi jennif
mcnealey cantata top-lin result on-going enrol solid
tumor myeloma combin trial upcom phase initi cystic fibrosi
primari focu lead glutaminas inhibitor telaglenastat remain track report
top-lin progression-fre surviv data registration-en cantata trial
first-in-class glutaminas inhibitor cabozantinib telaglenastat advanc metastat
addit intend initi phase trial evalu telaglenastat combin
chemo-immunotherapi frontlin nsclc patient tumor harbor
mutat believ nsclc patient harbor
alter confer sensit glutaminas inhibit telaglenastat
also support compani expect initi enrol expans
cohort renal cell cancer tripl neg breast cancer inhibitor ibranc
telaglenastat kra mutat colorectal/kra mutat lung cancer parp inhibitor
addit focu arginas inhibitor partner enrol
phase trial pembro chemo solid tumor darzalex
multipl myeloma remain on-going goal select one indic
move random phase trial
regard oral arginas inhibitor cystic fibrosi cf compani expect initi
phase studi placebo-control dose escal studi enrol
approxim patient regardless cf transmembran conduct regul cftr
mutat statu trial evalu multipl dose compar placebo ad
standard care focu safeti biomark includ nitrou oxid cftr function
well measur lung function
compani report secur llc estim price
phase fight futil analysi bemarituzumab gastric/gej cancer expect
cabiralizumab opdivo phase result
cabiralizumab opdivo phase result pancreat cancer
phase result keytruda ovarian cohort expect
prime one sever small-mid cap biotech compani end
littl cash unclear catalyst extend cash runway futil
analysi phase fight studi bemarituzumab frontlin gastric cancer
promin event see potenti no-win situat either futil studi allow
continu on-going spend difficult assess like outcom futil analysi given limit
data combin inhibit bemarituzumab would take
wait-and-se approach may no-win situat term pipelin beyond bemarituzumab
visibl antibodi cabiralizumab partner bristol-my squibb limit efficaci
data antibodi disappoint overal respons rate orr
fusion protein therapeut demonstr safeti across dose cohort to-dat
compani dose level expect rang efficaci may also chang
well fargo biotechnolog team met prime manag
investor meet san francisco focu meet chief strategi offic
secretari franci sarena cso dr helen collin evp cfo david smith martin forrest
vice-president ir corpor commun key clinic mileston bematuzumab
bema
octob paus enrol fight trial chemotherapi /- bema
therapi metastat gastric cancer order conduct futil analysi
overal surviv paus trigger unexpectedli high posit screen rate
overexpress gene amplif approxim vs
estim overal surviv month gastric cancer expect accru enough
event conduct futil analysi
also expect report phase data go/no go decis plu
keytruda ovarian cancer goal show respons rate
cell agonist dose patient cohort phase dose
escal trial dose clinic activ would expect addit continu dose
escal intend backfil biolog activ dose level patient shown
prior sensit checkpoint inhibitor patient could provid earli evid clinic
activ inform dose expans late day half-lif rel differ
affin believ everi week dose provid
continu inhibit cell checkpoint pathway pulsatil agon cell via
may reduc potenti cell anergi
also late expect announc phase random trial
chemotherapi /- cabiralizumab line pancreat cancer well potenti advanc
fprx-discov antibodi phase
follow restructur provid cash burn guidanc
approxim less cash compani suffici
cash fund oper howev compani interest possibl
ad earli stage clinic asset pipelin also highlight toxic profil
lend use antibody-drug conjug bispecif antibodi car-t
compani report secur llc estim price
phase result dpx-survivac low dose cyclophosphamid ldcpa ovarian cancer
phase basket data partner merck evalu dpx-survivac keytruda solid tumor
top-line result iit phase trial partner merck dpx-survivac keytruda
dlbcl
imv establish promis cancer vaccin opportun depovax dpx platform deliv
cancer antigen dendrit cell direct antigen-specif t-cell respons rel
emerg platform deliv cancer antigen dendrit cell includ mrna approach imv
differenti data dpx-base vaccin approach demonstr traffick dendrit cell
lymph node dose depend increas antigen specif t-cell respons notwithstand
potenti platform valu dpx-base cancer vaccin believ initi result lead vaccin dpx-
survivac remain mix limit evid monotherapi activ across sever trial recent data
american societi hematolog combin dpx-survivac keytruda diffus
larg b-cell lymphoma dlbcl highlight support complet respons seen
drug alon howev would note evid monotherapi opdivo
believ patient experi requir establish clear contribut dpx-survivac
focu like rotat phase go/no-go decis dpx-survivac solid tumor particular
ovarian cancer would take wait-and-se approach emerg data given prior mix result
well fargo biotechnolog team met imv inc imv manag investor
meet san francisco focu meet ceo freder or dr joann schindler
cfo pierr labb cancer vaccin dpx-survivac
ovarian cancer imv expect present top-lin data dpx-survivac refractori ovarian
cancer ahead compani event februari order
move registr studi imv need see least respons last month order
exclud respons rate expect salvag chemotherapi imv note key
opinion leader opin signific need intense-chemotherapy-fre option recal
imv use metronom dose cyclophosphamid dpx-survivac
move diffus larg cell lymphoma imv partner merck review updat data
investig initi trial evalu combin dpx-survivac keytruda
includ data least addit patient vs data report use protocol
defin efficaci elig criteria investig report complet partial respons
determin next step dlbcl imv intend determin contribut
keytruda defin best increas efficacy-elig popul consid either
replic inclus criteria strategi use kite pharma yescarta exclus
patient requir bridg chemotherapi apheresi car-t infus
allow bridg chemotherapi
imv also collabor basket trial evalu dpx-survivac keytruda
liver lung ovarian head neck high tumor late februari deadlin
abstract submiss imv expect submit data plan patient note
ovarian cancer patient cohort close fulli enrol imv expect
abl compar data ovarian cancer dpx-survivac monotherapi plu metronom
cyclophosphamid mci dpx-survivac keytruda without mci
beyond dpx-survivac imv intend move dpx-surmag phase dpx-surmag
target survivin mage phase investig expect
pharmacodynamic-focus neoadjuv trial includ muscl invas non-muscl
compani report secur llc estim price
result inhibitor opdivo solid tumor
data partner roch studi front line therapi tnbc rcc
infin pharmaceut infi differenti approach target myeloid deriv
suppressor cell mdsc implic immun suppress within tumor microenviron tme
overal respons rate orr cancer lead io drug candid disappoint
partial respons pr note patient evalu efficaci earli result phase
studi infi expand enrol target complet expect
detail data roughli patient treat overal includ combin
opdivo believ initi data reason opportun demonstr efficaci patient
tumor type associ high mdsc infiltr remain cautiou overal prospect
updat well initi data frontlin combin tripl neg breast
cancer tnbc renal cell cancer rcc believ urotheli cancer uc may
repres best opportun base data suggest diverg clinic outcom
mdsc-high mdsc-low patient timelin data extend beyond cash runway
concern view
biotechnolog team met infin pharmaceut infi manag
investor meet san francisco focu meet ceo adelen perkin presid
dr lawrenc bloch cso dr jeffrey kutok cfo seth tasker vice presid gener counsel
secretari first-in-class gamma select inhibitor develop
switch immunosuppress macrophag immunocompet macrophag
infi studi treatment refractori patient line patient mario-
frontlin patient phase trial cohort complet
enrol compani expect present addit data futur clinic trial
plan follow complet biomarker/correl analys includ tumor biopsi data
focu like melanoma treatment-refractori tripl neg
breast cancer tnbc initi data led cohort expans high myeloid deriv
suppressor cell mdsc cohort infi hypothesi circul mdsc could proxi
leverag data correl baselin mdsc surviv opdivo checkmat trial
support infi conduct trial line urotheli bladder
cancer patient high low mdsc random opdivo
opdivo infi expect complet enrol later top-lin data announc
support roch infi conduct front line patient either tnbc
receiv tecentriq plu nab-paclitaxel
renal cell cancer receiv tecentriq plu avastin tnbc
hypothesi determin revers immunosuppress macrophag
respons nab-paclitaxel induc tumor damage/hypoxia renal cell cancer
may neutral non-vegf angiogen factor secret macrophag
refractori tnbc also focu collabor run
trial combin arcuss adenosin receptor antagonist doxil infi
note triplet safe expans cohort open
compani report secur llc estim price
phase data vopratelimab /- checkpoint inhibitor advanc solid tumor
vopratelimab yervoy interim phase data nsclc uc expect
establish hypothesi phase icon studi ico
agonist vopratelimab suggest preferenti activ solid tumor patient icos-hi t-cell count
strategi induc icos-hi t-cell count inhibitor yervoy believ
hypothesi limit retrospect analysi subject sever area bia overli reliant
progress free surviv overal surviv os data sensit patient attribut
could confound hypothesi also look pursu second path
optim vopratelimab effect predict biomark os orr combin
inhibit believ biomark identifi icon phase potenti
sensit limit ultim respons pr gastric cancer pr
tnbc scchn nsclc icon phase studi believ support
vopratelimab activ still limit would advis wait-and-se approach emerg phase
updat success rate induct icos-hi cell yervoy dose durat vopratelimab
earli evid increas respons rate ico induct strategi
well fargo biotechnolog team met jounc therapeut manag
investor meet san francisco focu meet ceo dr richard murray
head ir strateg financ komal joshi lead ico agonist vopratelimab data
phase icon studi on-going enrol phase emerg combin studi
yervoy design predict biomark phase select trial
focu result icon manag highlight dec data cut-off
three patient treat vopra inhibitor remain studi month
follow-up patient ico hi cell emerg total cell
achiev recist orr month mpf month mo
move forward compani began enrol phase emerg combin studi
vopra yervoy experienc nsclc june mg/kg vopra dose
follow trial amend open enrol lower mg/kgvopra dose
expect patient receiv mg/kg yervoy follow vopra dose week later
option complet addit consecut cycl week interv vopra
continu diseas progress recal contrast patient icon receiv mg/kg
vopra everi week dose though result ico satur acceler
cell exhaust subject enrol emerg undergo scan everi week
enrol mg/kg dose complet enrol kg/mg dose on-going
clinic biomark data least nsclc patient expect
addit focu select random phase predict biomark studi vopra
in-hous vs io-nav second line nsclc expect
begin enrol patient interim clinic data expect patient
select use tumor rna signatur biomark assay develop predict patient
higher likelihood emerg ico hi cell sustain activ
low dose intermitt dose vopra manag estim use cutoff point associ
high degre posit neg predict second line nsclc
patient screen elig trial
addit manag highlight preclin develop treg deplet mab
data expect medic meet progress toward ind file
compani report secur llc estim price
partner argx initi phase anti-compl factor antibodi enhanz trial
partner roch intend submit sbla enhanz perjeta/herceptin
partner complet us eu regulatori submiss darzalex sc juli
expect us approv follow eu approv base standard review timelin
phase interim data conduct enhanz formul /-
opdivo subject solid tumor
follow wide anticip phase failur proprietari oncolog drug pancreat
cancer late halozym rapidli trim head count expens commit
enhanz busi model focus near term profit royalti partner
drug convert subcutan sc form enhanz technolog
commit return cashflow sharehold initi start aggress share repurchas
program believ tangibl sharehold valu expect beyond recur royalti
target includ cumul mileston period
exist royalti late cycl enhanz product herceptin sc mabthera sc
europ herceptin sc rituxan us see signific inflect royalti growth
expect approv darzalex sc sale opportun
expect approv co-formul
herceptin/perjeta sc anoth potenti sale opportun royalti
opportun see anoth valu inflect could anticip overal
estim npv current royalti darzalex sc herceptin/perjeta sc royalti
assum similar market dynam seen initi launch herceptin sc mabthera sc
europ would suggest signific option valu potenti high valu sc candid
develop preclin candid addit potenti deal
well fargo biotechnolog team met halozym senior manag
industri meet san francisco focu meet ceo dr helen torley cfo lauri
stelzer vice-president investor relations/corpor commun al kildani compani
enhanz platform expect enhanz mileston royalti growth earn outlook
key product mileston overal came away continu confid abil
drive sustain revenu earn growth enhanz mileston royalti payment
near term valu inflect expect launch darzalex sc
herceptin/perjeta sc continu progress partner program
focu recent transit enhanz busi manag highlight
revenu guidanc vs guidanc
first ever profit ep vs consensu estim
broken royalti vs mileston contribut revenu compani includ
signific contribut darzalex sc royalti follow expect approv
assum continu modest eros herceptin sc mabthera sc royalti europ
within guidanc royalti revenu expect inflect
darzalex sc herceptin/perjeta longer term growth toward
target partner pipelin progress
focu enhanz pipelin highlight drug phase expect
advanc phase one phase addit candid expect enter
phase highlight averag time phase initi approv
year compani believ improv upon pipelin program highlight
includ opdivo sc tecentriq sc ocrevu sc sc efgartigimod sc
target slot still avail enhanz partner expect addit deal
compani report secur llc estim price
june pdufa date sacituzumab govitecan antibodi drug conjug bla
phase data trophi sacituzumab govitecan subject metastat urotheli cancer
failur platinum-bas regimen base immunotherapi
commun registr strategi
phase data ascent sacituzumab govitecan refractory/relaps triple-neg breast
phase interim data sacituzumab govitecan prostat cancer subject progress
zytiga xtandi
follow resubmiss bla sacituzumab govitecan tnbc accept complet class
respons fda june pdufa continu see risk converg timelin
confirmatori ascent studi data potenti acceler approv recent recoveri share
believ expect earli approv advanc pdufa date base
recent earli approv categori like sickl cell diseas class review prior
manufactur issu believ schedul pre-approv inspect gate approv
contribut believ downsid risk extend review greater upsid potenti earli
approv potenti overlap pdufa top-line data ascent confirmatori studi
see risk studi success given potenti longer control group contempl
compani report secur llc estim price
phase data conduct helsinn histon deacetylas inhibitor hdac pracinostat
azacytidin hma-naiv subject ipss-r high/veri high risk md
phase dose escal monotherapi safety/efficaci combin safeti data cyclin-
depend kinas inhibitor voruciclib r/r cell malign initi
venclexta combin
phase combin cohort safeti initi efficaci data meip inhibitor
combin bgne btk inhibitor zanubrutinib r/r cell lymphoma
complet enrol pivot phase tidal trial follicular lymphoma subject
failur two prior system therapi
believ one under-appreci name target oncolog
categori sever potenti high profil drug progress toward registr enabl
studi primari focu lead inhibitor pivot develop follicular
lymphoma fl believ overal respons rate orr relapsed/refractori follicular
lymphoma fl chronic lymphocyt leukemia cll competit data emerg b-
cell cancer standard care revlimid rituxan bode well studi success ultim
approv believ inhibitor voruciclib also emerg signific valu driver
monotherapi combin therapi venclexta venetoclax particular
focu potenti synergi inhibit venclexta b-cell malign includ acut
myeloid leukemia aml follow recent high profil acquisit arqul arql merck
access novel non-coval btk inhibitor b-cell cancer resist first-gener
coval btk inhibitor believ combin inhibit voruciclib inhibit
venclexta could even better efficaci patient resist b-cell cancer final
expect remain low phase develop pracinostat aml follow prior disappoint
md see signific option valu initi data
well fargo biotechnolog team met pharma manag investor
meet san francisco focu meet ceo gold vice-president investor relat corpor
commun david walsey potenti best-in-class inhibitor novel
inhibitor voruciclib partner aml/md drug pracinostat highlight meet includ
updat durat respons progress free surviv phase data target
present complet enrol registration-en tidal line follicular
lymphoma trial initi data combin beigen bio btk
inhibitor brukinsa current focu optim dose view use earlier line
treatment singl agent voruciclib data advanc hematolog malign target present
announc initi venclexta combin data acut myeloid leukemia aml
expect pracinostat partner helsinn present phase myelodysplast syndrom data
potenti data posit commit phase trial companion aml trial
expect helsinn complet enrol
compani report secur llc estim price
commun recommend phase dose non-coval btk inhibitor vecabrutinib
initi enrol discret cohort patient relaps refractori cll btk
mutat r/r cll without btk mutat r/r cll venclexta failur cll
snss plan file ind first-in-class inhibitor upstream
effect valid target akt
expect sunesi pharmaceut snss make go/no-go decis non-coval btk inhibitor
vecabrutinib phase develop limit anti-tumor activ seen thu far
initi dose cohort believ full explor
effect dose rang thoroughli achiev longer term follow recent
initi dose cohort potenti escal dose cohort base
expert feedback prior pk/pd data vecabrutinib believ dose cohort
clearli sub-therapeut also subject sicker patient enrol competitor
vecabrutinib trough plasma concentr well predict efficaci rang
hope partial respons pr emerg increasingli dose
follow recent acquisit non-coval btk-inhibitor peer arqul arql merck
see upsid potenti phase dose identif far exceed downsid risk believ
snss disciplin preserv cash buffer downsid advanc go/no-go phase
dose decis said cash runway limit believ path forward beyond
dose mid-year timelin challeng would look earli sign sustain lymphocytosi
seen competitor potenti lead indic efficaci earlier
well fargo biotechnolog team met sunesi pharmaceut snss manag
investor meet san francisco focu meet interim ceo dayton
misfeldt cso evp dr judith svp commerci parvind hyar cfo svp
financ corpor develop william quinn non-coval btk inhibitor
vecabrutinib preclin inhibitor
vecabrutinib phase trial compani note dose-limit toxic period
cohort success complet patient slot
like final cohort fill compani expect present data
month scan cohort compani march investor updat data
first scan cohort expect follow decis transit phase
chronic lymphocyt leukemia cll patient achiev stabl diseas cohort
on-going cycl vs cycl dose depend sustain decreas
potenti biomark btk inhibit evid lymph node mass decreas
snss remain encourag emerg data vecabrutinib believ recommend
phase dose identifi cohort
snss expect file ind novel inhibitor consid
master kinas kinas pathway across cancer cell line compani
observ sensit mutat delet gene encod tumor
suppressor protein commonli mutat human cancer major
mutat tumor cell line show intermedi high sensit separ snss
note acquir resist breast cancer patient inhibitor associ
increas express long-stand target interest pharma to-
date develop inhibitor challeng pre-clin toxic snss
encourag success complet day non-glp toxicolog studi
compani report secur llc estim price
phase interim data conduct santen endoglin target mab lucenti vs
lucenti alon wet age-rel macular degener subject
phase data novel androgen receptor antagonist subject castrat
resist prostat cancer follow complet trial exclus option
reacquir opt-in payment plu expens
top-line data phase dose escal antibodi alon combin
tecentr subject advanc metastat cancer
tracon intend initi registr enabl studi sub-cutan administ
inhibitor envafolimab undifferenti pleomorph sarcoma
outlook tracon pharmaceut tcon balanc promis effici product
develop platform seri licens deal develop partner product nearer term balanc
sheet risk cautiou view upcom opt-in decis partner janssen androgen receptor
ar inhibitor prostat cancer santen endoglin inhibitor tcon
recent deal medicin jiangsu alphamab development/commerci could
repres differenti opportun differenti subq formul larg iv categori
success phase pk data support dose fda agreement pivot studi design
target orr unselect patient extens cash runway exist atm
equiti line potenti mileston opt-in janssen opt-
santen i-mab out-licens develop focus specif ar point
mutat data support efficaci beyond mutat limit term prospect santen
opt-in would note crowd natur develop limit success multipl vegf add-on
strategi disappoint result endoglin inhibit cancer overal would maintain
cautiou view tcon pend better visibl opt-in opportun prospect extend
cash runway
well fargo biotechnolog team met tracon pharmaceut tcon manag
investor meet san francisco focu meet ceo dr charl theuer
cbo mark wiggin chief account offic head financ scott brown
follow late licens envafolimab sarcoma medicin alphapharm
oncolog tcon expect cross-refer exist ind initi registration-en
singl arm trial advanc undifferenti pleomorph sarcoma diseas
approv treatment leverag exist relationship sarcoma
commun tcon expect conduct interim analysi full data assum
protocol modif interim follow approv late product launch
inhibitor approv tcon note patient dose
envafolimab shown equival efficaci keytruda opdivo across varieti
tumor investig initi trial keytruda demonstr
respons rate camelid antibodi envafolimab drug product concentr allow
subcutan administr assum price pariti current inhibitor month
durat dose advanc patient address popul approxim
patient per year tcon estim potenti market opportun
mid-teen doubl digit royalti owe full right sarcoma addit evalu
envafolimab front line tcon use biomark data advanc trial
evalu patient select strategi sarcoma sub-typ
tcon expect santen report data phase avant trial age-rel
macular degener follow phase decis could trigger
mileston payment tcon well make opt-in decis prostat
cancer would trigger mileston provid tcon asset believ would
attract potenti chines partner i-mab
tcon continu dose ahead decis tcon i-mab initi
co-develop phase tcon expect make opt-in decis first
bispecif antibodi opportun tcon would make up-front payment prior
file ind tcon expect file first bispecif antibodi file
envafolimab i-mab program requir tcon make up-front payment incur
compani report secur llc estim price
phase interim data repotrectinib inhibitor subject
posit advanc nsclc ntrk-posit solid tumor
phase interim data inhibitor subject solid tumor
despit tripl valu turn market cap post-
ipo view share attract valu rel lead targeted-oncolog peer like
blueprint medicin valuat loxo oncolog acquisit eli lilli
sever target oncolog opportun overlap loxo oncolog includ repotrectinib
ntrk mutat cancer ret mutat cancer believ tptx
differenti chemistri emerg clinic profil potenti advantag loxo trk inhibitor
vitrakvi larotrectinib ret inhibitor particular would note activ repotrectinib
wild-typ mutat common solvent-front resist mutat well high respons
rate tki naiv tki-experienc metastasi expert feedback suggest could support
frontlin osit believ emerg best-in-class profil repotrectinib mutat
cancer ration engin uniqu macrocycl chemistri support best-in-class
properti repotrectinib ntrk-mutat cancer well ret-mut cancer
recent provid corpor updat highlight key mileston across
primari focu lead product candid repotrectinib inhibitor
phase registr portion studi phase studi pediatr
patient continu advanc earli interim data initi patient trident-
registr cohort expect
recal base on-going dialog health agenc recent amend
protocol expans cohort clarifi advanc nsclc patient must
one prior platinum-bas chemotherapi regimen addit one prior tki cohort
two prior tki cohort base propos treatment paradigm cohort expans
amend enrol advanc nsclc patient one prior tki
prior chemotherapi goal expand enrol across multipl advanc
also announc repotrectinib grant track design
treatment advanc nsclc patient previous treat one prior
line platinum-bas chemotherapi one prior line tki line
cohort patient popul addit preclin repotrectinib combin data expect
addit focu inhibitor on-going phase clinic trial
advanc solid tumor patient genet alter continu advanc earli
interim data initi patient expect studi design assess overal
safeti toler pk preliminari efficaci standard dose escal design follow
dose expans recommend phase dose set total enrol
portion studi expect approxim patient
ret/src inhibitor on-going phase trial continu progress
note earli enrol multipl ret patient solvent-front mutat
previous treat investig ret inhibitor open-label trial expect
enrol approxim patient phase dose escal approxim patient
phase dose expans portion assess safeti profil preliminari efficaci
regard pipelin develop announc nomin next-gener
inhibitor recent advanc ind-en studi preclin data
expect ind submiss anticip earli
compani report secur llc estim price
zyme bgne intend initi phase potenti registr enabl trial
biparatop antibodi subject biliari cancer
zyme bgne intend initi phase potenti registr enabl random trial
cisplatin/capecitabin herceptin high line gastric cancer trial
zyme conduct neoadjuv monotherapi chemotherapi combin trial breast
zymework zyme emerg top manufactur develop bispecif antibodi
therapeut progress across separ high profil collabor well signific advanc
potenti best-in-class bispecif antibodi therapeut target solid tumor indic focu
lead biparatop antibodi believ data patient advanc breast cancer
gastric cancer fail prior therapi competit daiichi sankyo lead
antibodi drug conjug clear safeti toler advantag full
approv strategi frontlin gastric cancer head-to-head categori leader herceptin
acceler approv strategi advanc biliari tract cancer gastroesophag adenocarcinoma
gea zyme fast-to-market strategi expand opportun strategi larg
categori collabor beigen serv acceler develop provid access
larg market china ultim view signific valu driver zyme
antibodi drug conjug initi safeti efficaci data expect daiichi
sankyo benchmark overal respons rate orr refractori breast
cancer base strong efficaci base antibodi expect signific increment anti-
tumor effect conjug toxin expect superior efficaci safeti compar
would note conjug toxin associ pulmonari toxic limit
would note much higher orr higher dose limit pulmonari
well fargo biotechnolog team met zymework zyme manag
investor meet san francisco focu meet ceo dr ali tehrani dr ryan
dercho corpor develop novel biparatop antibodi
follow proof-of-concept data posit metastat biliari tract cancer btc
zyme partner beigen intend initi registr enabl trial line btc
plan bla file
compani intend start registr enabl trial compar
chemotherapi versu trastuzumab chemotherapi line gastric cancer
patient potenti cohort ad inhibitor plu chemo
breast cancer zyme initi neoadjuv trial monotherapi combin plu
standard care soc chemo versu soc chemo-immunotherapi complement recent
initi support trial ibranc fulvestr line hormon receptor
posit metastat breast cancer patient follow proof concept zyme
expect initi phase trial patient whose tumor express level
requir classifi broadli zyme expect leverag excel
safeti profil target agent
zyme also provid updat phase dose escal trial note
patient dose-limit toxic clinic meaning
evid anti-tumor activ observ treatment-rel advers event observ
to-dat grade except singl case grade diarrhea
fulli revers case grade event success manag
outpati importantli cardin microtubul inhibitor mti -relat toxic high
grade neutropenia/thrombocytopenia neuropathy/neurotox observ zyme
intend continu dose escal qualifi therapeut window identifi dlt ahead
initi expans cohort low express breast gastric cancer
partner beigen
compani report secur llc estim price
pegzilarginas pivot phase peac enrol complet follow top-line
data
phase data pegzilarginas sclc
ind file homocystinuria
ind file cystinuria
aeglea biotherapeut clearli demonstr signific sustain reduct
serum arginin pegzilarginas patient arginas defici easili achiev
primari endpoint peac phase studi less convinc regard level support
clinic endpoint includ measur improv mobil particular focu walk test
believ measur subject high variabl train effect difficult
interpret without control arm meter overal improv baselin meter
improv respond defin respond appear impress believ data
difficult extrapol phase peac studi result placebo control similarli
assess gross motor function gmfm includ gmfm part gmfm-e focus walk
run jump believ improv baselin difficult interpret without
control group ultim believ arginin reduct absenc statist signific
improv secondari measur mobil would unlik support approv absenc
better control phase data better insight natur histori measur expect
control group behavior would take cautiou view peac studi data appear
anticip around expect regulatori updat earli context
breakthrough therapi design pegzilarginas believ acceler approv path
phase data alon unlik full peac studi data requir approv
compani report secur llc estim price
transcon pth phase path forward data hypoparathyroid follow end phase
meet fda
transcon hgh bla submiss submiss
transcon phase interim acomplish data achondroplasia
believ ascendi pharma asnd clearli establish differenti best-in-class
platform improv deliveri conveni therapeut profil biolog drug across separ
high-valu rare endocrin diseas transcon deliveri technolog signific upsid
potenti realiz posit phase height studi result transcon hgh
statist signific improv height veloc daili growth hormon gh see
upsid potenti phase path forward transcon pth patient hypoparathyroid
program phase transcon patient achondroplasia primari focu earli
path forward result transcon pth believ respons criteria serum urin
calcium normal along discontinu calcium vitamin repres unpreced
profil one would establish new standard care versu exist pth replac brand
natpara well lower cost calcium vitamin supplement base prior phase result
demonstr differenti effect serum urin calcium expect high respond rate
path forward could support fast market strategi context unmet need recent
natpara market withdraw overal expect three separ opportun emerg
believ current valuat repres first opportun
ascendi pharma asnd held investor event san francisco recent follow earlier
announc outlook preliminari data open label extens portion
ole path forward studi focu event progress regulatori file
transcon hgh pediatr growth hormon defici ghd path forard ole data
regulatori strategi transcon pth hypoparathyroid develop progress
transcon achondroplasia earlier pipelin program
focu statu bla file transcon hgh pediatr ghd asnd note
track bla file file data packag complet
height studi nearli complet flight studi enlighten process clinic
summari document expect complet mid-april document end march
asnd highlight recent long-term extens data on-going enlighten studi
continu demonstr statist superior growth patient receiv transcon hgh
height switch studi asnd note fda shown interest data show treatment
differ preserv year enlighten studi ask see data cut
suggest possibl mention data label subject fda discret regard
question possibl advisori committe adcomm asnd note
believ reason adcomm part expans strategi asnd plan initi
phase trial adult ghd well initi trial pediatr ghd japan
focu transcon pth asnd highlight preliminari data ole portion
phase path forward studi show subject longer requir activ vitamin
longer requir calcium supplement remain one subject take
multivitamin less mg calcium asnd highlight transcon pth product
profil replac therapi rather adjunct therapi natpara asnd
continu enrol patient recent expand phase path forward trial
expect top-lin result expect march six-month result ole
expect
term regulatori strategi transcon pth asnd expect discuss new data fda
regard potenti breakthrough therapi design btd asnd note prior btd
discuss base healthi volunt data agenc ask patient data asnd
believ agenc need asnd expect pivot packag includ
roughli patient initi week double-blind treatment month ole
asnd also plan start confirmatori phase trial soon phase trial
focu transcon achondroplasia asnd expect conduct two phase trial
goal pursu acceler approv pathway asnd continu advanc phase
accomplish trial children ach plan escal sequenti dose cohort throughout
recent agreement china-partn visen asnd expect
second phase trial children ach initi soon accomplish trial
regard earlier pre-clin program oncolog asnd highlight recent data transcon
beta/gamma non-human primat nhp demonstr bias receptor bind
prolong enhanc lymphocyt count suggest feasibl three-week dose asnd
expect file ind first oncolog program
compani report secur llc estim price
ind file p-selectin modul inclacumab treatment vaso-occlus crise voc scd
believ market new therapi sickl cell diseas scd begin period
signific sustain growth similar seen last year myeloma categori
global blood therapeut forefront much like celgen forefront
myeloma categori growth last two decad patient scd us versu
multipl myeloma recent approv gbt oral polymer inhibitor oxbryta
voxelotor novartiss p-selectin antibodi adakveo crizanlizumab emerg cur
transplant option believ similar market dynam emerg seen myeloma
oral revlimid backbon therapi potent antibodi therapeut like velcade/ kynamro darzalex
promin use transplant overal believ emerg therapi scd led could
readili support market opportun us alon like seen myeloma unlik celgen
potenti domin posit categori treatment includ oral backbon therapi
recent approv oxbryta best-in-class p-selectin antibodi inclacumab recent collabor
oral fetal hemoglobin hf induc agent could compet cur transplant option focu
oxbryta launch expect secur reimburs earlier expect beat
consensu estim readili initi sale trend may difficult interpret first month
launch expect provid patient number proxi commerci experi ultim
broadest label possibl underli polymer inhibitor patient
hemolyt anemia proxim downstream consequ see signific initi demand
oxbryta drive share price appreci
biotechnolog team met manag
investor meet san francisco focu meet ceo dr ted david
johnson cfo jeffrey farrow progress oxbryta launch focu expand drug
access on-going dialogu payer recent initi dose escal studi support
primari focu oxbryta launch manag expect provid first launch metric
earn call note strong uptak patient hub first six week access
compani sale forc continu target physician specialist primari
care estim see scd preval popul expect launch
oxbrtya brand speaker bureau februari follow fda approv brand educ
materi note current physician base
follow approv conduct medic review major payer key
state encompass scd patient expect major formulari review
conclud gbt initi feedback payer broad access
prior author restrict label step edit limit physician attest
patient offer fail hydroxyurea hu highlight emerg alreadi
group high prescrib note earli success get medic except
reimburs compani also expect launch direct-to-pati ad campaign pend
fda review end
addit manag highlight recent initi oxbryta open-label dose escal
patient start dose escal sequenti
maximum dose full data studi expect earli potenti
support snda dose escal regimen inform potenti dose target next
gener molecul manag also highlight on-going enrol multi-year
transcranial-doppl tcd confirmatori studi patient expect tcd veloc
cm/sec studi power detect mean chang tcd veloc addit
focu categor chang stroke risk evalu primari endpoint mean tcd chang
week treatment control arm also expect initi wearabl
devic actigraphi studi character mobil sleep activ patient oxbryta
well report studi data decemb
pipelin develop manag note signific progress manufactur
transfer roch p-selectin mab inclacumab treatment voc expect
initi pivot studi commerci scale product recent syro deal also
highlight provid potenti futur valu driver uniqu small molecul approach
compani report secur llc estim price
obetichol acid oca nash pdufa march follow launch
ocaliva phase data pbc
share intercept pharmaceut doubl low octob vs nbi
sinc see addit upsid potenti fda panel review potenti
approv obetichol acid oca first drug non-alcohol steatohepat nash
therapi demonstr statist signific revers nash liver fibrosi breakthrough
therapi design btd fda believ likelihood posit recommend approv
high particular obetichol acid oca alreadi approv broadli use hepatologist
primari biliari cholang pbc brand ocaliva see littl risk approv believ
fda panel review focus nash categori broadli establish risk/benefit
benchmark futur drug review addit focu tangibl market opportun identifi
patient treatment within estim nash patient us would note
estim sale reflect penetr patient biopsi proven nash
see signific upsid potenti adopt non-invas test broadli
diagnos patient expert feedback proprietari survey work suggest strong support oca
nash believ non-invas test propos particularli combin
predict par commonli use nit heart diseas exampl overal
view nash opportun sizeabl given distinct benefit oca broad failur effort
expect signific larg pharma focu oca nash
compani report secur llc estim price
pioneer open label extens ole week result expect
phase data dilat cardiomyopathi dcm
approach pivot year phase explor data myosin
modul mavacamten obstruct hypertroph cardiomyopathi ohcm detail
expect maverick phase studi non-obstruct hcm nohcm continu expect
mavacamten respons rate peak /- nyha improv pioneer phase
exceed explor phase optim echo-driven dose support signific phase
benefit control group respons expect come maverick phase detail
earlier expect peak increas nyha improv similar seen
pioneer studi replic non-obstruct hcm repres signific increment valu
driver question rais late implic left ventricular eject fraction lvef
reduct small number patient maverick believ detail earli establish
clear separ dose caus lvef reduct dose requir efficaci addit
would gener lvef reduct nohcm offset improv lvot gradient arent
present risk lvef reduct ohcm offset improv lvot gradient expect
lvef reduct minim see addit option valu emerg
dilat cardiomyopathi dcm genet defin popul hfref well
advanc pipelin myosin modul
biotechnolog team met manag investor
meet san francisco focu meet ceo tasso gianakako cfo taylor harri
svp medic scienc dr marc semigran compani pipelin oral myosin
modul genet heart diseas upcom explor phase data lead myosin
modul mavacamten obstruct hypertroph cardiomyopathi ohcm recent maverick
phase data mavacamten non-obstruct hcm nohcm implic hfpef
popul pipelin progress danicamtiv dilat cardiomyopathi dcm
well next-gener drug overal came away continu
confid prospect posit explor data clear path forward nohcm
hfpef indic increment valu dilat cardiomyopathi dcm subpopul
focu upcom phase explor data ohcm expect top-line data
includ detail primari endpoint respond rate well key secondari endpoint lvot
gradient reduct peak improv nyha class improv well
exploratori endpoint remain confid prospect posit explor data base
earlier pioneer phase result optim echo-guid dose explor over-
power studi note explor power assum drop rate
drop rate well addit addit focu potenti risk
eject fraction chang dose escal toward lvot gradient elimin see less
risk nohcm limit impact note posit pioneer data even dose wasnt
addit focu recent maverick phase result nohcm submit late
breaker abstract march meet know shortli accept
altern could report data may esc heart failur meet earlier
press releas despit heterogen fill pressur nohcm highlight
pioneer-lik benefit peak nyha class patient subgroup elev
fill pressur pre-specifi high risk group eject fraction seen
maverick reduct expect impact efficaci defin popul nohcm
thought less risk nohcm also plan advanc
mavacamten hfpef indic potenti fast-follow
compani report secur llc estim price
ind file pah
adolesc data phase qsymia trial
vivu vvu roughli quarter target quarter turn around believ earli
assess prospect success singl quarter sequenti growth earli sign
growth weight loss drug qsymia pancreat enzym insuffici treatment pancreaz
encourag continu see headwind challeng market signific competit
reimburs difficulti primari focu qsymia perform would challeng view
poor histor growth function mis-execut instead would suggest structur barrier
market includ histor poor patient persist therapi lose weight stop treatment dont lose
weight stop treatment physician comfort low cost phentermin potenti on-going
tent prescrib remain follow fen phen debacl follow decad
underwhelm brand weight loss sale remain skeptic qsymia substanti
sustain turn around given rel low cash posit rel high debt burden would
maintain cautiou view toward vvu share pend longer term prescript data evid
transform growth
compani report secur llc estim price
phase data advis trail etrasimod atop dermat
olorinab phase result patient ibd/ibs-associ pain
attract valu cash high valu partnership ralinepag unit
pah on-going phase studi best-in-class modul etrasimod ulcer
timelin etrasimod uc phase data extend expect phase data
etrasimod atop dermat ad phase data olorinab ib signific valu driver
reiter overweight rate arena pharmaceut follow recent
corpor outlook call primari focu new program etrasimod eosinophil
esophag eoe alopecia areata aa believ biolog rational preclin data
data compet oral agent etrasimod data immunolog indic support
strong basi develop continu view attract valu
cash best-in-class inhibitor ulcer coliti crohn diseas emerg
data atop dermat new program announc eoe aa view expand
beacon discoveri effort inflamm new effort neuroinflamm support longer
arena pharmaceut host confer call earlier today review new
strateg plan includ expans phase develop modul etrasimod
establish wholli own subsidiari arena neurosci focu microgli
neuroinflamm expect phase phase read-out
next year compani intend file one new ind per year
primari focu call lead modul etrasimod intend initi
phase program crohn diseas phase program eosinophil esophag eoe
phase program alopecia areata aa program expand on-going late-stag
etrasimod program ulcer coliti phase atop dermat phase behind
etrasimod olorinab oral peripher act agonist cannabinoid receptor cb
current phase develop abdomin pain associ irrit bowel syndrom
select receptor antagonist current phase test
beyond clinic pipelin announc expand collabor beacon discoveri
project cabrillo appli arna gpcr expertis target immunolog
inflamm format arena neurosci wholli own subsidiari focus
compani report secur llc estim price
phase data lead fcrn drug candid efgartigimod myasthenia gravi mg
patient adapt studi
fcrn drug competitor report data phase studi mg immunov
phase data efgartigimod pemphigu vulgari pv
go/no-go decis efgartigimod chronic inflammatori demyelin polyneuropathi cidp
base data first patient stage phase adher trial expect
go/no-go decis although exact time depend speed enrol
argenx argx leader emerg categori fcrn drug autoimmun diseas
continu see balanc benefit-risk stock current valuat believ critic
year better clariti term competit risk well fcrn opportun beyond myasthenia gravi
mg believ proof-of-concept data mg competitor momenta immunov
import watch comparison may drawn vs argx efgartigimod term
dose frequenc efficaci profil argx phase data mg also critic focu
replic efficaci profil seen phase addit phase data pemphigu vulgari pv
phase go/no-go decis chronic inflammatori demyelin polyneuropathi cidp
potenti import implic confirm opportun fcrn antagonist
broader autoimmun indic opinion
argx earlier today held investor event san francisco discuss design phase
adapt studi compani fcrn antagonist efgartigimod gener myasthenia gravi
gmg review recent announc phase data efgartigimod pemphigu vulgari
pv increment detail
phase adapt studi announc earlier complet enrol total
top-line data expect enrol criteria phase consist
previou phase studi phase studi enrol gmg patient mg-adl score
least without background therapi without autoantibodi achr
enrol stratifi background therapi achr antibodi
adapt patient treat cycl begin four once-weekli infus
mg/kg efgartigimod placebo follow treatment remaind cycl
studi durat week time treatment cycl individu
determin durat sustain treatment benefit follow studi period
patient enter open-label extens initi treatment four once-weekli
dose efgartigimod follow retreat need simul clinic practic
primari endpoint studi proport respond first
treatment cycl achr patient respons defin improv least mg-adl
point least consecut week time within first treatment cycl
argx note design novel dose regimen adapt base efgartigimod phase
data fast onset action within week durabl respons sustain week
argx also note physician patient prefer treatment diseas
activ payor cost consciou
phase studi efgartigimod pv argx provid addit detail addit data
mucosal-dominant/mucocutaneous/cutaneous/pf sever mild moder
patient treat four once-weekli infus efgartigimod follow weekli
biweekli mainten dose variabl frequenc agrx present data show declin
pdai activ time correl decreas antibodi
level argx highlight fast onset action major diseas control achiev
infus deep respons clinic remiss cr optim dose regimen
time cr week mean maximum pdai improv strong steroid
compani report secur llc estim price
interim phase data marina trial aiha itp
lupu nephriti phase data
attract valu rel proof-of-concept achiev sle clear efficaci skin joint
system featur lupu
signific upsid opportun favor therapeut index confirm step
dose earli phase experi across lupu nephriti ln dermatomyositis/polymyos
ultim expect posit proof-of-concept across indic base prior experi non-
select proteasom inhibitor velcad earli data sle
compani report secur llc estim price
phase proof-of-concept data lead fcrn drug candid nipocalimab myasthenia gravi mg
vivacity-mg studi
phase proof-of-concept data hypersialyl ivig product candid immun
thrombocytopenia itp
continu view attract valu opportun lead fcrn drug nipocalimab
autoimmun diseas proof-of-concept phase data myasthenia gravi mg emerg
expect nipocalimab demonstr potenti best-in-class efficaci support best-in-class
igg reduct well differenti dose schedul everi week everi week addit
thrombocytopenia itp although major part thesi given academ debat
role hypersialyl ivig function could lead signific upsid posit given larg
opportun myriad autoimmun diseas ivig use
hypersialyl ivig product candid
well fargo biotech team met manag investor meet san
francisco focu meet dr young kwon chief busi offic
dr santiago arroyo new data report morn compani
hyersialyl ivig product candid well progress lead anti-fcrn antibodi
nipocalimab program encourag initi proof-of-concept itp
mnta plan expand program cidp high-valu indic given widespread
use ivig nipocalimab program would highlight potenti breakthrough
therapi design btd hdfn addit opportun broader fetal-matern
autoimmun diseas well major catalyst phase data mg
design studi interrog initi depth igg reduct overal area
curv total igg level reiter overweight rate
focu report earlier morn interim data phase studi
immun thrombocytopenia itp multi-part studi current part evalu
singl ascend dose mg/kg mg/kg follow singl dose ivig
note patient first cohort mg/kg per cohort
respond achiev platelet count least one patient respond
actual receiv mg/kg rather design dose mg/kg due infus pump
failur one patient mg/kg dose respond patient
respond subsequ ivig either base earli favor respons
variabl respons ivig increas number patient part also includ
lower dose cohort given observ respons seen mg/kg mg/kg
plan report addit data part also announc plan
initi studi chronic inflammatori demyelin polyneuropathi cidp later
focu anti-fcrn mab nipocalimab report phase vivacity-mg
studi myasthenia gravi mg enrol data track phase uniti
studi hemolyt diseas fetu newborn enrol patient data track
expect seek breakthrough therapi design phase studi
warm autoimmun hemolyt anemia waiha activ site eu
enrol patient data expect around
also announc nomin earli develop sifbodi candid
sifbodi platform ind-en studi begin addit fc-trimer
product candid partner report phase heathi
volunt studi remain on-going plan introduc subcutan formul
also note year-end cash provid guidanc full-year non-
caaap oper expens
compani report secur llc estim price
ind file mr ibd
ind file ipf
focu develop conformation-select oral integrin inhibitor across varieti diseas
includ inflamm fibrosi believ morphic therapeut platform highli
leverag substanti valid approv antibodi therapeut target variou integrin
receptor particular believ entyvyio vedolizumab success ulcer coliti uc
crohn diseas cd significantli valid morf oral integrin inhibitor
expect ind file abbvie-partn alpha-v beta inhibitor
valid ipf advanc antibodi therapeut pipelin ind file
expect increas focu disrupt platform multi-billion dollar inject
well fargo biotechnolog team met morphic therapeut manag
investor meet san francisco focu meet presid ceo dr praveen tipirneni
chief scientif offic dr bruce roger senior vice presid chri erdman
develop progress strateg direct compani pipelin oral integrin
focu compani wholly-own lead program target highlight
select product candid select two advanc compound
note high select select strong
preclin safeti profil expect make ind file treatment
inflammatori bowel diseas ibd begin clinic studi term
competit landscap note field oral thin
program develop reason competitor compound may
encount difficulti maintain pharmacokinet pk properti given larg peptid
vs small-molecul compound expect present preclin pk nhp data
european crohn coliti organ ecco meet februari vienna
austria full nhp data receptor occup pk data digest diseas week ddw
meet may chicago term long-term strategi note high level
extern interest partnership especi purpos combin therap believ
eventu partner hand plan develop short-term
clinic studi obtain pk receptor occup data hand partner
focu abbvie-partn program target treatment
idiopath pulmonari fibrosi note announc previous ind file delay
fda request toxicolog data one speci normal cours pre-ind
interact note fda request occur coincident termin
antibodi phase trial safeti reason although clear whether
safeti concern relat target antibodi
also highlight earli pipelin program includ target tgf-beta activ solid
tumor turn cold tumor hot applic tumor colon cancer
fibrot diseas tgf-beta activ fibrot diseas collabor well
collabor program janssen
lastli note strong cash posit cash runway
compani report secur llc estim price
phase data partner sanofi trial multipl sclerosi
phase cohort expans data solid tumor
expect revers coval btk inhibitor demonstr deepen respons best-in-class
profil separ autoimmun diseas itp pemphigu
expect longer term dose ole data confirm better efficaci rituxan pemphigu fcrn
drug well approv tavaliss itp
addit upsid potenti phase ms data sanofi-partn btk inhibitor
optim blood brain barrier penetr support improv efficaci competitor merck kga
new trial initi announc follow lead fcrn antibodi broader autoimmun
compani report secur llc estim price
phase proof-of-concept data inhibitor atop dermat ad
phase proof-of-concept data inhibitor cancer includ respons rate data
phase portion evalu monotherapi combin keytruda
viral associ charg tumor
continu see great potenti rapt novel cell homing-target drug candid could
larg opportun highli preval allerg inflammatori diseas atop dermat
asthma initi proof-of-concept lead immunolog product candid emerg mid-
continu see opportun oral competitor blockbust inject
drug dupix potenti safer altern emerg high profil jak inhibitor also see
addit option valu immuno-oncolog drug novel mechan target regulatori
cell charg tumor import proof-of-concept data sever viral associ
charg tumor
biotechnolog team met manag
investor meet san francisco focu meet ceo dr brian wong cfo
rodney young compani oral inhibitor develop
allerg diseas oncolog highlight meet includ clean safeti
profil allow high dose mg dose need achiev target receptor
occup test phase atop dermat proof-of-concept data new
preclin data show compar efficaci vs dupix mous ad model
continu progress phase studi without keytruda phase
studi charg tumor proof-of-concept data track
focu note phase healthi volunt studi singl dose
mg exceed target receptor occup compani expect
evalu dose highest dose test phase multiple-dos phase studi
ad patient given safeti profil proof-of-concept data phase studi remain
track recal phase studi enrol roughli patient moderate-to-
sever ad random treatment vs placebo also plan
conduct phase studi ad evalu three dose level highest dose
mg vs placebo ad patient per group also present new preclin
data compar vs dupix ad mous model demonstr similar efficaci
addit focu note enrol combin cohort
phase studi charg tumor recal phase studi evalu
monotherapi keytruda variou viral associ charg tumor
proof-of-concept data expect recommend phase dose mg target
engag demonstr mg phase healthi volunt studi
regard previous report nsclc patient refractori tecentriq achiev
complet respons cr keytruda phase portion studi note
patient still dose close month respons also comment
patient tecentriq close year prior enrol studi
therefor late respons tecentriq also quot expert describ
likelihood refractori patient respond anoth less
never lastli note nsclc patient despit mg dose clear
target engag
compani report secur llc estim price
ticker rate note
